US 12,215,152 B2
Humanized anti-human CD19 antibodies and methods of use
Claudia Ferrara Koller, Zug (CH); Guy Georges, Habach (DE); Alexander Haas, Weilheim (DE); Hubert Kettenberger, Munich (DE); Ekkehard Moessner, Kreuzlingen (CH); Tilman Schlothauer, Penzberg (DE); Michael Molhoj, Munich (DE); and Laurent Lariviere, Munich (DE)
Assigned to Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed by Hoffmann-La Roche inc., Little Falls, NJ (US)
Filed on Jan. 19, 2022, as Appl. No. 17/578,655.
Application 17/578,655 is a continuation of application No. 15/763,868, granted, now 11,286,300, previously published as PCT/EP2016/073412, filed on Sep. 30, 2016.
Claims priority of application No. 15187820 (EP), filed on Oct. 1, 2015.
Prior Publication US 2022/0204616 A1, Jun. 30, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/00 (2006.01); C07K 16/28 (2006.01); C12P 21/08 (2006.01)
CPC C07K 16/2803 (2013.01) [C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 8 Claims
 
1. An antibody that specifically binds to human CD19, wherein the antibody comprises:
(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03,
(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11,
(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05,
(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 40,
(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and
(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08.